A health crisis alert has been issued in Kerala, where authorities have taken a bold step to protect public safety. The state government has banned a total of 17 medicines, including 10 allopathic drugs and 7 Ayurvedic arishtas, due to concerns over their quality and safety. This move is part of an intensified effort to combat counterfeit and substandard medications, ensuring drug safety for the people of Kerala.
The Battle Against Unsafe Drugs: A Necessary Step
The recent ban on these medicines follows a series of actions taken by the Drugs Control Department. Last month, a major seizure of counterfeit inhaler medicines used by asthma patients prompted authorities to take action against two pharmaceutical companies: Aswas Pharma in Thiruvananthapuram and Med World Pharma in Thrissur.
But here's where it gets controversial: the list of banned medicines includes both allopathic and Ayurvedic formulations. This decision has sparked debates among health professionals and the public, as it raises questions about the regulation and quality control of traditional Ayurvedic medicines.
Banned Ayurvedic Medicines and Their Validity
The banned Ayurvedic medicines, each with a validity of ten years from their manufacturing date, are as follows:
- Amritarishtam (Batch 0110)
- Kanakasavam (0114)
- Ashwagandharishtam (111)
- Usirasavam (0117)
- Kudajarishtam (0113)
- Abhayarishtam (109) - all from Karunagappally Bala Herbals
- Ashokaristam (0220) - from Karunagappally Shiva Ayurvedic Pharmaceuticals
Allopathic Medicines Under Scrutiny
In addition to the Ayurvedic medicines, several allopathic drugs have also been banned due to quality concerns:
- Rabeprazole Sodium Tablets IP 20 mg (Torab) by OAKSUN Lifesciences, Telangana, batch T25.018, expiring in December 2026
- Montelukast and Levocetirizine Tablets (Lecet-M) by Spinka Pharma, batch LCM-5061, expiring in May 2027
- Glimepiride Tablets IP 2 mg by Kerala State Drugs and Pharmaceuticals Ltd., batch GL 4142, expiring in October 2026
- Ranitidine Oral Solution IP (Raani Drops) by Sresan Pharmaceuticals, batch SR-017, expiring in May 2026
- Aceclofenac and Paracetamol Tablets (Richnac-P) by J M Laboratories, Himachal Pradesh, batch GT16375A, expiring in October 2026
- Cyproheptadine Hydrochloride Syrup (Hepsandin Syrup) by Sresan Pharmaceuticals, batch SR-086, expiring in November 2026
- Clopidogrel and Aspirin Tablets (Clopidomed A-150) by Ikon Pharmachem, Dehradun, batch T250139, expiring in December 2026
- Calcium and Vitamin D3 Tablets IP by Bangal Chemicals and Pharmaceuticals Ltd., batch T572514, expiring in July 2026
- Clopidogrel and Aspirin Tablets IP by Theon Pharmaceuticals, batch GT250375, expiring in January 2027
- Paracetamol and Tramadol Hydrochloride Tablets (Tracet) by Chimak Healthcare, batch LBHK25001, expiring in January 2028
- Ciprofloxacin Hydrochloride Tablets IP 500 mg (Ciprodac-500) by Cadila Pharmaceuticals, batch JKBD24080, expiring in July 2027
Authorities have urged pharmacies, hospitals, and patients to immediately cease selling or consuming these medicines. This crackdown is a crucial part of Kerala's ongoing battle to ensure drug safety and protect its citizens from the dangers of counterfeit pharmaceuticals.
And this is the part most people miss: the impact of such decisions on public health and the pharmaceutical industry. It raises important questions about the balance between regulating traditional medicines and ensuring access to safe and effective treatments.
What are your thoughts on this issue? Do you think the ban on these medicines is a necessary step to protect public health, or is there a better way to address the problem of counterfeit drugs? Share your insights and opinions in the comments below!
